Insitro — Portfolio Company | Sahin Boydas Angel Investments Machine learning-driven drug discovery and development.
Written by Sahin Boydas — serial entrepreneur, 2x exited founder, and angel investor in 207+ startups including OpenAI, Anthropic, Scale AI, and Hugging Face.
About Insitro
Machine learning-driven drug discovery and development. Insitro represents the kind of company I look for as an angel investor — strong technical founders building in a large market with clear differentiation.
Sector: Biotech
Why I Invested
Insitro caught my attention because of the team's deep domain expertise and their unique approach to solving a fundamental problem in biotech. The market opportunity is massive, and the team has the technical chops to capture it.
Investment Thesis
My investment in Insitro reflects my broader thesis on biotech:
- Large addressable market — The biotech market is growing rapidly with significant room for disruption
- Strong technical moat — The team has built proprietary technology that's difficult to replicate
- Proven execution — Early traction demonstrates product-market fit and team capability
- Network effects — The product gets better as more users adopt it
Related Investments
Other companies in my portfolio working in biotech and adjacent spaces:
Frequently Asked Questions
What does Insitro do?
Machine learning-driven drug discovery and development.
Why did Sahin Boydas invest in Insitro?
Insitro represents a compelling opportunity in biotech with strong technical founders, a large market, and clear product-market fit. The investment aligns with my thesis on backing category-defining companies early.
What sector is Insitro in?
Insitro operates in the biotech sector, which is one of the fastest-growing areas of technology investment.
How does Insitro fit in Sahin's portfolio?
Insitro is one of 207+ angel investments in my portfolio, which spans AI, fintech, robotics, developer tools, healthcare, and more. I look for companies with strong technical moats and large addressable markets.